Article thumbnail

Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging

By A. Fangberget, L. B. Nilsen, K. H. Hole, M. M. Holmen, O. Engebraaten, B. Naume, H.-J. Smith, D. R. Olsen and T. Seierstad
Topics: Breast
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:3088808
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2002). Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
  2. (2009). Age and Her2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol 20:636–641 Eur Radiol
  3. (2001). Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume -a serial CT scan-based study.
  4. (2008). Breast MRI: guidelines from the European Society of Breast Imaging.
  5. (2009). Cancer in Norway
  6. (2001). Diffusion and perfusion MRI: basic physics.
  7. (2006). Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer.
  8. (2010). Diffusion-weighted MRI for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
  9. (2007). Diffusion-weighted MRI in the body: applications and challenges in oncology.
  10. (2008). Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results.
  11. (2003). Incremental value of ADC as an indicator of treatment response in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
  12. (2009). Is there concordance of invasive breast cancer pathologic tumor size with magnetic resonance imaging?
  13. (2004). Locally advanced breast cancer comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.
  14. (2009). Longitudinal study of the assessment by MRI and diffusionweighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
  15. (2007). Measurements of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
  16. (2004). Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
  17. (2006). MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy.
  18. (2008). MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
  19. (2006). Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy.
  20. (2009). New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1).
  21. (2006). Prediction of clinicopathological response of breast cancer to primary chemotherapy at contrast-enhanced MR-imaging: initial clinical results.
  22. (2001). Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.
  23. (2001). Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
  24. (2009). Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.
  25. (2007). Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
  26. (2005). Taghian A
  27. (2010). The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: a preliminary study.
  28. (2004). version 2.0. IARC,